================================================================================

                     U.S. SECURITIES AND EXCHANGE COMMISSION

                              WASHINGTON, DC 20549

                                   ----------


                                   FORM 12b-25

                           Notification of Late Filing


                                   ----------


    [ ] Form 10-K [ ] Form 11-K [ ] Form 20-F [X] Form 10-QSB [ ] Form N-SAR


                        For Quarter Ended: March 31, 2002


Nothing in this Form shall be construed to imply that the Commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:

                                       N/A
--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
PART I - REGISTRANT INFORMATION
--------------------------------------------------------------------------------

                         Fountain Pharmaceuticals, Inc.
                -------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

                         505 S. Westland Avenue, Suite D
                                 Tampa, FL 33606
                      -------------------------------------
                     (Address of Principal Executive Office)

================================================================================



--------------------------------------------------------------------------------
PART II - RULES 12B-25 (B) AND (C)
--------------------------------------------------------------------------------

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)

         (a)      The reasons described in reasonable detail in Part III of this
                  form could not be eliminated without unreasonable effort or
                  expense;

[X]      (b)      The subject annual report or semi-annual report/portion
                  thereof will be filed on or before the fifteenth calendar day
                  following the prescribed due date; or the subject quarterly
                  report/portion thereof will be filed on or before the fifth
                  calendar day following the prescribed due date; and

         (c)      The accountant's statement or other exhibit required by Rule
                  12b-25(c) has been attached if applicable.


--------------------------------------------------------------------------------
PART III - NARRATIVE
--------------------------------------------------------------------------------

State below in reasonable detail the reasons why the Form 10-KSB, 11-K, 20-F,
10-QSB or N-SAR or portion thereof could not be filed within the prescribed
time:

         The Company's limited resources were consumed by management's efforts
         to make an acquisition, the closing of which has temporarily been
         postponed. Due to this reason, the Company was unable to complete this
         filing on a timely basis without unreasonable effort and expense.


--------------------------------------------------------------------------------
PART IV - OTHER INFORMATION
--------------------------------------------------------------------------------

(1)      Name and telephone number of person to contact in regard to this
         notification

         Joel C. Schneider, Esq.            (516) 228-8181

(2)      Have all other periodic reports required (under Section 13 or 15(d) of
         the Securities and Exchange Act of 1934 or Section 30 of the Investment
         Company Act of 1940) during the preceding 12 months (or for such
         shorter period that the registrant was required to file such reports)
         been filed? If answer no, identify report(s).

                  [X]  YES                                    [ ]  NO



(3)      Is it anticipated that any significant change in results of operations
         from the corresponding period for the last fiscal year will be
         reflected by the earnings statement to be included in the subject
         report or portion thereof?

                  [X]  YES                                    [ ] NO

         If so, attach an explanation of the anticipated change, both
         narratively and quantitatively, and; if appropriate, state the reasons
         why a reasonable estimate of the results can not be made.

                  A qualitative and quantitative statement cannot be provided at
                  this time, for reasons set forth in Part III above.


         Fountain Pharmaceuticals, Inc. has caused this notification to be
signed on its behalf by the undersigned thereunto duly authorized.


Dated:  May 15, 2002                        Fountain Pharmaceuticals, Inc.



                                            By:   /s/ Brendon K. Rennert
                                                -------------------------------
                                                  Brendon K. Rennert, President


--------------------------------------------------------------------------------
                                    ATTENTION
            Intentional misstatements or omissions of act constitute
                Federal Criminal Violations (See 18 U.S.C. 1001).
--------------------------------------------------------------------------------